You have no items in your shopping cart.
MARK2 phospho T595 Antibody
Description
Images & Validation
−| Tested Applications | ELISA, WB |
|---|---|
| Dilution range | ELISA: 1:1,000 - 1:3,000, WB: 1:250 - 1:1,000 |
| Reactivity | Human |
| Application Notes |
Key Properties
−| Antibody Type | Primary Antibody |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Immunogen | This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to amino acids surrounding T595 of Human MARK2 isoform a. The immunogen peptide was phosphorylated at the residue corresponding to T595. |
| Purity | MARK2 pT595 affinity purified antibody is directed against the phosphorylated form of human MARK2 at the pT595 residue. The product was affinity purified from monospecific antiserum by immunoaffinity chromatography. Antiserum was first purified against the phosphorylated form of the immunizing peptide. The resultant affinity purified antibody was then cross-adsorbed against the non-phosphorylated form of the immunizing peptide. Reactivity occurs against human MARK2 pT595 protein and the antibody is specific for the phosphorylated form of the protein. Reactivity with non-phosphorylated human MARK2 is minimal by ELISA. Expect at least partial reactivity with other isoforms of MARK. The immunogen sequence is present in all forms identified to date and localizes to T595 on MARK2, T587 on MARK3, T591 on MARK1 and T568 on MARK4. A BLAST analysis was used to suggest reactivity with this protein from human, dog, bovine, mouse and rat sources based on 100% homology for the immunogen sequence. Cross reactivity with MARK2 homologues from other sources has not been determined. |
| Conjugation | Unconjugated |
Storage & Handling
−| Storage | Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use. |
|---|---|
| Form/Appearance | Liquid (sterile filtered) |
| Buffer/Preservatives | 0.01% (w/v) Sodium Azide |
| Concentration | 1.0 mg/mL |
| Dry Ice Shipping | Please note: This product requires shipment on dry ice. A dry ice surcharge will apply. |
| Disclaimer | For research use only |
Alternative Names
−
Quality Guarantee
Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Western Blot of Rabbit anti-MARK2pT595 antibody. Lane 1: 293T cells untransfected. Lane 2: 293T cells transfected with MARK2 (EMK1) and PKC-zeta. Lane 3: 293T cells transfected with MARK2 (EMK1). Load: 35 µg per lane. Primary antibody: MARK2pT595 antibody at 1:1000 for overnight at 4°C. Secondary antibody: IRDye800™ rabbit secondary antibody at 1:10000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: ~83kDa kDa for MARK2 pT595. Other band(s): MARK2pT595 splice variants and isoforms.

Western Blot of Rabbit anti-MARK2pT595 antibody. Lane 1: wild type Jurkat cells. Lane 2: wild type Jurkat cells stimulated with CD3/CD28 (T-cell receptor stimulation). Load: 35 µg per lane. Primary antibody: MARK2 pT595 antibody at 1:500 for overnight at 4°C. Secondary antibody: IRDye800™ rabbit secondary antibody at 1:10000 for 45 min at RT. Block: 5% BLOTTO overnight at 4°C. Predicted/Observed size: ~83 kDa for MARK2pT595.
Documents Download
Request a Document
Protocol Information
MARK2 phospho T595 Antibody (orb345521)
Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.
Login to Submit a Review